Popular disinfectants do not kill HPV

 

Penn State, PA USA (February 12, 2014) – Commonly used disinfectants do not kill human papillomavirus (HPV) that makes possible non-sexual transmission of the virus, thus creating a need for hospital policy changes, according to researchers from Penn State College of Medicine and Brigham Young University.

"Because it is difficult to produce infectious HPV particles for research, little has been known about HPV susceptibility to disinfection," said Craig Meyers, Distinguished Professor of Microbiology and Immunology, Penn State College of Medicine.

 

Use of disinfectants on HPV in health care settings has been based on what works on other viruses or what is thought should be effective.

 

Meyers collaborated with Richard Robison, an expert in microbial disinfectants at Brigham Young University.

 

HPV is estimated to be among the most common sexually transmitted diseases and is linked to cervical cancers. For this study, researchers grew HPV16, a specific strain that is responsible for up to 60 percent of all HPV-associated cancers. They then used 11 common disinfectants on the virus.

 

These disinfectants included ones made of ethanol and isopropanol because these are common ingredients in surface disinfectants and hand sanitizers used in both public and health care settings. Study of these hand sanitizers is important because other research has shown high levels of HPV DNA on fingers of patients with current genital infections. While HPV is susceptible to certain disinfectants, including hypochlorite and peracetic acid, it is resistant to alcohol-based disinfectants.

 

"Chemical disinfectants in hand sanitizer are commonly used in the general population to prevent the spread of infectious diseases," Meyers said. "For flu or cold viruses they are very effective. But the data shows that they do nothing for preventing the spread of human papillomavirus."

 

They also tested other common disinfectants, including glutaraldehyde, which is used for sterilization in medical and dental facilities. Results show that glutaraldehyde is not effective at inactivating the HPV virus.

 

Results were published in the Journal of Antimicrobial Chemotherapy.

 

Other research has suggested that HPV could be transmitted non-sexually. The current study shows that medical instruments considered sterile could pose a risk for transmission.

 

"Chemical disinfectants used in the hospitals and other healthcare settings have absolutely no effect on killing human papillomavirus," Meyers said. "So unless bleach or autoclaving is used in the hospital setting, human papillomavirus is not being killed and there is a potential spread of HPV through hospital acquired or instrument or tool infection."

 

Meyers said the results suggest a need for a change in disinfectant use policies.

 

 

Other scientists on this project were Jordan Meyers, Brigham and Woman’s Hospital, formerly of Brigham Young University; and Eric Ryndock and Michael J. Conway, Department of Microbiology and Immunology, Penn State College of Medicine.

 

The National Institute of Allergy and Infectious Disease of the National Institutes of Health and the BYU Mentoring Environment Grant program funded this research.

 


 

Penn State, 12.02.2014 (tB) Thomas Backe

MEDICAL NEWS

Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…
Starting the day off with chocolate could have unexpected benefits
Better mental health supports for nurses needed, study finds

SCHMERZ PAINCARE

Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…
Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern

DIABETES

„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Toujeo® bei Typ-1-Diabetes: Weniger schwere Hypoglykämien und weniger Ketoazidosen 
Bundestag berät über DMP Adipositas: DDG begrüßt dies als Teil…
Mit der Smartwatch Insulinbildung steuern
Verbände fordern bessere Ausbildung und Honorierung von Pflegekräften für Menschen…

ERNÄHRUNG

Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen
Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren

ONKOLOGIE

Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!
Deutsch-dänisches Interreg-Projekt: Grenzübergreifende Fortbildungskurse in der onkologischen Pflege
Sotorasib: Neues Medikament macht Lungenkrebs-Patienten Hoffnung

MULTIPLE SKLEROSE

NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen
Verzögerte Verfügbarkeit von Ofatumumab (Kesimpta®)
Neuer Biomarker bei Multipler Sklerose ermöglicht frühe Risikoeinschätzung und gezielte…
Multiple Sklerose beginnt oft lange vor der Diagnose
Goldstandard für Versorgung bei Multipler Sklerose

PARKINSON

Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…
Gemeinsam gegen Parkinson: bessere Therapie durch multidisziplinäre Versorgung